OASIS-5 trial - Summary & Results at ESC

714 views
612 views

Published on

http://www.theheart.org/web_slides/1136777.do

Fifth Organization to Assess Strategies in Acute Ischemic Syndromes

Published in: Health & Medicine, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
714
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
23
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

OASIS-5 trial - Summary & Results at ESC

  1. 1. OASIS-5 (Fifth Organization to AssessStrategies in Acute Ischemic Syndromes)
  2. 2. OASIS-5 (Fifth Organization to Assess Strategies in AcuteIschemic Syndromes)S Yusuf (McMaster University, Hamilton, ON)European Society of Cardiology 2005 Congress• Background: Fondaparinux is the first of a new class of antithrombotic drugs: selective factor-Xa inhibitors• Population and treatment: 20 078 patients randomized within 24 hours of an ACS to fondaparinux (2.5 mg subcutaneously once daily) or enoxaparin (1 mg/kg twice daily) for two to eight days• Primary outcomes: Primary efficacy outcome: a composite of death/MI/refractory ischemia at day 9 Primary safety outcome: rate of major bleeding at day 9
  3. 3. OASIS-5: Results (efficacy)• Fondaparinux is as effective as enoxaparin in the reduction of the primary efficacy end point: HR 1.01 (95% CI 0.90–1.13)Efficacy results at day 9End point Enoxaparin Fondaparinux (n=10 021), % (n=10 057), %Death/MI/refractory ischemia 5.8 5.9Death/MI 4.1 4.1Death 1.9 1.8MI 2.7 2.7Refractory ischemia 1.9 2.05
  4. 4. OASIS-5: Results (safety)• 47% reduction in major bleeds at day 9 with fondaparinux• Net clinical benefit—combination of efficacy and bleeding results—at day 9 with fondaparinux (HR 0.82 , 95% CI 0.74–0.90; p<0.00001)Bleeding results at day 9End point Enoxaparin Fondaparinux HR (95% CI) p (n=10 021), % (n=10 057), %Total bleeds 7.0 3.2 0.44 (0.39–0.51) <0.0001Major bleeds 4.0 2.1 0.53 (0.45–0.62) <0.0001TIMI major bleeds 1.3 0.7 0.54 (0.41–0.73) <0.0001Minor bleeds 3.1 1.1 0.35 (0.28–0.43) <0.0001
  5. 5. OASIS-5: Commentary*"This new drug . . . has a net clinical benefit at no greater financial cost." - Dr Salim Yusuf"There is no doubt in my mind that this drug is preferable to enoxaparin. Physicianswill have to think twice or thrice before prescribing enoxaparin after seeing thesereductions in bleeding and mortality with fondaparinux." - Dr Shamir Mehta (co– lead investigator)"This is a great situation that we have previously only dreamed about." - Dr Robert Califf *All comments from OASIS-5/Michelangelo: Dramatically reduced bleeding favors fondaparinux over enoxaparin in ACS (http://www.theheart.org/article/554453.do)
  6. 6. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×